Search Results - "Bellos, Nicholas"

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials by Clotet, Bonaventura, Dr, Bellos, Nicholas, MD, Molina, Jean-Michel, MD, Cooper, David, MD, Goffard, Jean-Christophe, MD, Lazzarin, Adriano, MD, Wöhrmann, Andrej, MD, Katlama, Christine, Prof, Wilkin, Timothy, MD, Haubrich, Richard, Prof, Cohen, Calvin, MD, Farthing, Charles, MD, Jayaweera, Dushyantha, MD, Markowitz, Martin, MD, Ruane, Peter, MD, Spinosa-Guzman, Sabrina, MD, Lefebvre, Eric, MD

“…Summary Background The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination…”
Get full text

Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation by Eron, Joseph J, Bartlett, John A, Santana, Jorge L, Bellos, Nicholas C, Johnson, Judy, Keller, Amy, Kuritzkes, Daniel R, St. Clair, Marty H, Johnson, Victoria A

“…Antiretroviral (ARV) treatment decisions are difficult for HIV-1-infected patients on complex treatment regimens who have partial suppression of HIV-1…”
Get full text

Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients by Hill, Andrew M, Clotet, Bonaventura, Johnson, Margaret, Stoll, Matthias, Bellos, Nicholas, Smets, Erik

“…Background: Very few studies have evaluated the cost of highly active antiretroviral therapy (HAART) per successful treatment in HIV-infected patients…”
Get full text

Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients: The POWER Experience by Hill, Andrew M., Clotet, Bonaventura, Johnson, Margaret, Stoll, Matthias, Bellos, Nicholas, Smets, Erik

“…Background : Very few studies have evaluated the cost of highly active antiretroviral therapy (HAART) per successful treatment in HIV-infected patients…”
Get full text

Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure: Results of a Pharmacokinetic Study of Enfuvirtide in HIV-1-Infected Patients With Impaired Kidney Function by Tebas, Pablo, Bellos, Nicholas, Lucasti, Christopher, Richmond, Gary, Godofsky, Eliot, Patel, Indravadan, Chiu, Yu-Yuan, Evans, Claire, Rowell, Lucy, Salgo, Miklos

“…OBJECTIVE:The aim of this study was to examine the influence of kidney disease and hemodialysis on the pharmacokinetics of enfuvirtide. DESIGN:An open-label,…”
Get full text

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2 : a pooled subgroup analysis of data from two randomised trials. Commentary by MACARTHUR, Rodger D, CLOTET, Bonaventura, HAUBRICH, Richard, COHEN, Calvin, FARTHING, Charles, JAYAWEERA, Dushyantha, MARKOWITZ, Martin, RUANE, Peter, SPINOSA-GUZMAN, Sabrina, LEFEBVRE, Eric, BELLOS, Nicholas, MOLINA, Jean-Michel, COOPER, David, GOFFARD, Jean-Christophe, LAZZARIN, Adriano, WÖHRMANN, Andrej, KATLAMA, Christine, WILKIN, Timothy

Get full text

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients by Squires, Kathleen E, Young, Benjamin, DeJesus, Edwin, Bellos, Nicholas, Murphy, Daniel, Sutherland-Phillips, Denise H, Zhao, Henry H, Patel, Lisa G, Ross, Lisa L, Wannamaker, Paul G, Shaefer, Mark S

“…The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by…”
Get more information

Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection by WHEAT, L. Joseph, FARTHING, Charles, COHEN, Calvin, PIERONE, Gerald, LALEZARI, Jay, PILSON, Robert S, SIEMON-HRYCZYK, Peggy

“…The objective of this study was to determine whether a triple therapy regimen incorporating twice-daily saquinavir is as effective as a three-times daily…”
Get full text